In addition, ibrutinib not only inhibits the secretion of chemokines, such as CCL3, CCL4, CXCL12 and CXCL13, from CLL cells and their supporting cells but also inhibits the TLR signaling pathway. Here, CXCL12 is linked to B-cell chronic lymphocytic leukemia.